Zacks Investment Research downgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a buy rating to a hold rating in a research report report published on Wednesday morning.

According to Zacks, “Tandem Diabetes Care, Inc. is a medical device company. The Company designs, develops, and commercializes products for people with insulin-dependent diabetes. Its products include t:slim Insulin Delivery System. Tandem Diabetes Care, Inc. is headquartered in San Diego, California. “

Other equities analysts have also recently issued research reports about the company. Robert W. Baird reaffirmed a hold rating and issued a $3.00 price target on shares of Tandem Diabetes Care in a report on Sunday, November 19th. Piper Jaffray Companies reaffirmed a hold rating and issued a $15.00 price target on shares of Tandem Diabetes Care in a report on Friday, October 6th. Finally, Wedbush reaffirmed an outperform rating and issued a $17.00 price target (down previously from $50.00) on shares of Tandem Diabetes Care in a report on Tuesday, October 10th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $11.29.

Shares of Tandem Diabetes Care (NASDAQ:TNDM) traded up $0.10 on Wednesday, hitting $2.56. The stock had a trading volume of 284,666 shares, compared to its average volume of 396,876. Tandem Diabetes Care has a 1 year low of $2.15 and a 1 year high of $30.00. The company has a current ratio of 1.90, a quick ratio of 0.88 and a debt-to-equity ratio of -2.70.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Thursday, October 26th. The medical device company reported ($3.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.74) by $0.65. The company had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.92 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 79.45%. Tandem Diabetes Care’s quarterly revenue was up 119.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.97) EPS. research analysts predict that Tandem Diabetes Care will post -15.37 EPS for the current fiscal year.

In other Tandem Diabetes Care news, CEO Kim D. Blickenstaff purchased 285,700 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, October 13th. The stock was bought at an average price of $3.50 per share, with a total value of $999,950.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 20.90% of the company’s stock.

Several institutional investors have recently made changes to their positions in TNDM. Bank of America Corp DE raised its holdings in shares of Tandem Diabetes Care by 88.6% during the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock valued at $1,032,000 after acquiring an additional 404,452 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Tandem Diabetes Care by 93.3% during the second quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock valued at $465,000 after acquiring an additional 280,551 shares during the last quarter. Keybank National Association OH raised its holdings in shares of Tandem Diabetes Care by 32.7% during the second quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock valued at $235,000 after acquiring an additional 72,177 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Tandem Diabetes Care by 2.7% during the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock valued at $987,000 after acquiring an additional 32,991 shares during the last quarter. Finally, Wedbush Securities Inc. raised its holdings in shares of Tandem Diabetes Care by 88.6% during the third quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock valued at $138,000 after acquiring an additional 88,709 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: “Tandem Diabetes Care (TNDM) Downgraded by Zacks Investment Research” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/16/tandem-diabetes-care-tndm-downgraded-by-zacks-investment-research.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.